Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Kinex Gains China Rights to Cancer Program from Hanmi

publication date: Jul 10, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Kinex Pharma of New York State extended its relationship with South Korea’s Hanmi Pharma by gaining the right to lead Hanmi’s Orascovery program development in China. The Orascovery program is developing oral treatments for cancer from known infused chemotherapies. In 2011, Kinex licensed rights to Orascovery for many countries, though not China. The 2011 agreement included $34 million of upfront and milestone payments to Hanmi. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...